ALS News Today Home | ALS News Today
Oct 17, 2024 · An advisory committee from the European Medicines Agency (EMA) has upheld its opinion against granting conditional marketing authorization to AB Science’s masitinib as an oral add-on treatment for amyotrophic lateral sclerosis (ALS) in the European Union. The decision was taken in a meeting by the Committee for Medicinal….
Types of Amyotrophic Lateral Sclerosis (ALS) – ALS News Today
Mar 8, 2023 · Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that can be classified into different types based on factors like genetics, a patient’s family history, and the disorder’s early symptoms. Across all types, ALS is marked by the loss of motor neurons, the nerve cells that control voluntary muscle movements ...
Phase 1 clinical trial of experimental ALS therapy AKV9 to soon...
Aug 28, 2023 · Akava Therapeutics will soon launch a Phase 1 clinical trial to test AKV9, its investigational therapy for amyotrophic lateral sclerosis (ALS), in healthy people. The trial follows the clearance of Akava’s investigational new drug (IND) application by the U.S. Food and Drug Administration (FDA). It will be AKV9’s first-in-human study and is ...
Clene granted in-person FDA meeting on CNM-Au8 for ALS
Sep 24, 2024 · Clene has been granted an in-person meeting with the U.S. Food and Drug Administration (FDA) — to be held before the end of November, according to the company — to discuss a potential accelerated approval of CNM-Au8 as a treatment for amyotrophic lateral sclerosis (ALS). Under such a pathway, the FDA may authorize a new therapy based on ...
Finding an ALS milestone moment in a visit to the skin doctor
Sep 17, 2024 · Keeping my anxieties in check, I waited patiently while my dermatologist assessed my skin. At the end of the exam, he proclaimed, “Your skin looks just fine, I’ll see you back here in a year.”. A wave of relief washed over me. But before my anxiety gremlins disappeared completely, I pointed to several minuscule bumps dotting my arms and legs.
Short course of treatment with RNS60 extends survival in ALS
Sep 23, 2024 · A short course of treatment with Revalesio ‘s RNS60 as an add-on to standard amyotrophic lateral sclerosis (ALS) therapies extended the median survival of people with the progressive disease by about six months compared with a placebo. That’s according to up to six years of data from an investigator-sponsored Phase 2 clinical trial ...
How the power of music brought meaning to life with ALS
Sep 20, 2024 · Music took on a deeper significance to both of us when Jeff was diagnosed with ALS in the fall of 2018. The news was unfathomable and shocking, and his diagnosis sent us both into a deep and isolating sadness. For the first time, our house was quiet and devoid of music. There was no artist or tune that could help process this news.
Man controls Alexa with thoughts via brain-computer interface
Sep 19, 2024 · The 64-year-old man, identified in a Synchron press release as Mark, lost the function of his upper limbs due to ALS. He was implanted with the BCI as part of a clinical trial. While control of Alexa devices typically involves the ability to tap a screen or speak, Mark is able to use his thoughts to directly control his smart home via the Tap to Alexa feature on an Amazon Fire tablet, Synchron ...
Phase 3 trial of oral pridopidine in treating ALS likely this year
Jan 29, 2024 · The Phase 2/3 pridopidine arm (NCT04615923) enrolled 163 adults with clinically possible, probable, or definite ALS, whose symptoms had started within the last three years. Participants were randomly assigned to oral pridopidine (45 mg) or a matched placebo taken twice daily for 24 weeks, or about six months. This was followed by an open-label ...
Early Signs of Bulbar Disease in ALS May Be Evident in the Tongue
Oct 4, 2016 · At early stages of the disease, a reduction in the size and duration of tongue movements was seen, while as speaking ability further deteriorated, the speed of tongue movements further slowed and the speed of jaw movements increased. These results indicated that tongue movement can be an appropriate marker of early changes in bulbar function.